Iterum Therapeutics plc

Equities

ITRM

IE000TTOOBX0

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-18 pm EDT 5-day change 1st Jan Change
1.63 USD +11.64% Intraday chart for Iterum Therapeutics plc +0.62% -17.26%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Iterum Therapeutics Plans to Engage Financial Advisor to Evaluate Strategic Alternatives CI
HC Wainwright Upgrades Iterum Therapeutics to Buy From Neutral, Price Target is $6 MT
Transcript : Iterum Therapeutics plc - Special Call
Iterum Therapeutics Says UTI Drug Trial Met Primary Endpoint DJ
Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections CI
Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023 CI
Transcript : Iterum Therapeutics plc, Q3 2023 Earnings Call, Nov 14, 2023
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections CI
Transcript : Iterum Therapeutics plc, Q2 2023 Earnings Call, Aug 11, 2023
Iterum Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Iterum Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Iterum Therapeutics plc, Q4 2022 Earnings Call, Mar 16, 2023
Transcript : Iterum Therapeutics plc, Q3 2022 Earnings Call, Nov 10, 2022
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q3 Loss $-0.43, vs. Street Est of $-0.92 MT
Iterum Therapeutics Reports Dosing First Patient in Late-Stage Urinary Tract Infections Trial MT
Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections CI
Iterum Therapeutics Files $100 Million Mixed-Securities Shelf MT
Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral Sulopenem CI
Iterum Therapeutics plc(NasdaqCM:ITRM) dropped from S&P Global BMI Index CI
Wall Street Futures Tumble Ahead of Fed Minutes MT
Top Premarket Decliners MT
Iterum Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q2 Loss $-0.03 MT
Chart Iterum Therapeutics plc
More charts
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.63 USD
Average target price
6.5 USD
Spread / Average Target
+298.77%
Consensus